• IGH/MAFB PLUS Translocation
  • IGH/MAFB PLUS Translocation
  • IGH/MAFB PLUS Translocation

IGH/MAFB PLUS Translocation

Hematoloji problari
Probe specification IGH, 14q32.33, Green MAF, 16q23, Red The IGH/MAF Plus v2 Translocation, Dual Fusion Probe consists of the IGH probe mix, labelled in green, proximal to the Constant segment and within the Variable segment of the IGH region and the MAF probe mix, labelled in red, that encompasses the MAF gene and flanking regions as well as the WWOX gene. Probe information MAF (MAF bZIP transcription factor) gene is located at 16q23 and IGH (immunoglobulin heavy locus) at 14q32.3. Approximately 50-60% of multiple myeloma (MM) cases are associated with translocations involving IGH and one of several partners including CCND1, NSD2 (WHSC1) and FGFR3, CCND3, MAF or MAFB1. The t(14;16)(q32.3;q23) translocation is a recurrent translocation seen in 2-10% of MMs1.
Product code : LPH 077

Probe specification

IGH, 14q32.33, Green

MAF, 16q23, Red

The IGH/MAF Plus v2 Translocation, Dual Fusion Probe consists of the IGH probe mix, labelled in green, proximal to the Constant segment and within the Variable segment of the IGH region and the MAF probe mix, labelled in red, that encompasses the MAF gene and flanking regions as well as the WWOX gene.

Probe information

MAF (MAF bZIP transcription factor) gene is located at 16q23 and IGH (immunoglobulin heavy locus) at 14q32.3. Approximately 50-60% of multiple myeloma (MM) cases are associated with translocations involving IGH and one of several partners including CCND1, NSD2 (WHSC1) and FGFR3, CCND3, MAF or MAFB1. The t(14;16)(q32.3;q23) translocation is a recurrent translocation seen in 2-10% of MMs1.

The majority of the breakpoints occur within the last intron of WWOX (WW domain containing oxidoreductase), centromeric to MAF. These breakpoints have a dual impact of positioning the IGH enhancer near MAF and disrupting the WWOX gene2. Gene expression profiling of myeloma cell lines revealed that MAF caused transactivation of cyclin D2 (a promoter of cell cycle progression), thus enhancing proliferation of myeloma cells3.

According to the literature, MM patients harbouring the t(14;16) appear to have a more aggressive clinical outcome4,5.

Downloadable Files

Technical document Download